Catalyst Pharmaceutical Partners Regains Compliance With NASDAQ Minimum Bid Price Rule

Catalyst Pharmaceutical Partners Regains Compliance With NASDAQ Minimum Bid
Price Rule

CORAL GABLES, Fla., Aug. 2, 2013 (GLOBE NEWSWIRE) -- Catalyst Pharmaceutical
Partners, Inc. (Nasdaq:CPRX), a specialty pharmaceutical company focused on
the development and commercialization of novel prescription drugs targeting
rare (orphan) neuromuscular and neurological diseases, announced today that it
has received notice from the NASDAQ Stock Market ("NASDAQ") on August 2, 2013
confirming that the Company has regained compliance with the $1.00 per share
minimum bid price requirement for continued listing on the NASDAQ Capital
Market.

As previously announced, on December 24, 2012, NASDAQ notified the Company
that the bid price of its common stock had closed at less than $1.00 per share
over the previous 30 consecutive trading days and, as a result, the Company
was not in compliance with Listing Rule 5550(a)(2)("Rule"), the minimum bid
price rule. The Company was provided 180 calendar days, or until June 24, 2013
to regain compliance with the Rule. Additionally, on June 25, 2013, NASDAQ
notified the Company that it had been granted an additional 180-day extension
period, or until December 23, 2013, in which to regain compliance with the
Rule.

On August 2, 2013, NASDAQ notified the Company that the closing bid price of
its common stock has been at $1.00 per share or greater at least 10
consecutive trading days. Accordingly, NASDAQ has confirmed to the Company
that it has regained compliance with the minimum bid price rule and the matter
is now closed.

About Catalyst Pharmaceutical Partners

Catalyst Pharmaceutical Partners, Inc. is a specialty pharmaceutical company
focused on the development and commercialization of novel prescription drugs
targeting rare (orphan) neuromuscular and neurological diseases, including
Lambert-Eaton Myasthenic Syndrome (LEMS), infantile spasms, and Tourette
Syndrome. Catalyst's lead candidate, Firdapse™ for the treatment of LEMS, is
currently undergoing testing in a global, multi-center, pivotal phase III
trial. Catalyst is also developing a potentially safer and more potent
vigabatrin analog (designated CPP-115) to treat infantile spasms, and
epilepsy, as well as other neurological conditions associated with reduced
GABAergic signaling, like post-traumatic stress disorder, Tourette Syndrome,
and movement disorders.

Forward-Looking Statements

This press release contains forward-looking statements. Forward-looking
statements involve known and unknown risks and uncertainties, which may cause
Catalyst's actual results in future periods to differ materially from
forecasted results. A number of factors, including whether Catalyst will
continue to remain in compliance with the Nasdaq listing standards, as well as
those factors described in Catalyst's Annual Report on Form 10-K for the
fiscal year 2012 and other filings with the U.S. Securities and Exchange
Commission (SEC), could adversely affect Catalyst. Copies of Catalyst's
filings with the SEC are available from the SEC, may be found on Catalyst's
website or may be obtained upon request from Catalyst. Catalyst does not
undertake any obligation to update the information contained herein, which
speaks only as of this date.

CONTACT: For Further Information Contact:
         Patrick J. McEnany
         Catalyst Pharmaceutical Partners
         Chief Executive Officer
         (305) 529-2522
         pmcenany@catalystpharma.com
        
         Melody Carey
         Rx Communications Group
         Co-President
         (917) 322-2571
         mcarey@rxir.com
 
Press spacebar to pause and continue. Press esc to stop.